Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242725 | 0.96 | CACNA2D1 (0.34) | ACHECACNA2D1SLC6A2GRM4IGF1R | |
| SCHEMBL366145 | 0.92 | ACHE (0.36) | ACHEGRM4 | |
| SCHEMBL368225 | 0.89 | ACHE (0.37) | ACHECACNA2D1SLC6A2GRM4IGF1R | |
| SCHEMBL367809 | 0.89 | ACHE (0.34) | ACHEGRM4 | |
| SCHEMBL16242988 | 0.88 | FGFR3 (0.37) | ACHEGRM4 | |
| SCHEMBL15302907 | 0.88 | ACHE (0.37) | ACHEGRM4 | |
| SCHEMBL16242838 | 0.88 | SMN1; SMN2 (0.35) | ACHE | |
| SCHEMBL15302887 | 0.88 | ACHE (0.34) | ACHEGRM4 | |
| SCHEMBL16242733 | 0.87 | SIGMAR1 (0.34) | ACHEGRM4 | |
| SCHEMBL16242632 | 0.87 | ACHE (0.33) | ACHEGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765091-B2 | Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-2592932-B1 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| EP-2592932-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009001-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRIK4 | ACHE 839/4885CACNA2D1 924/4885SLC6A2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.